Parabilis Medicines
PBLS
28.82
-0.04
-0.14%
Parabilis Medicines
US · PBLS
#2366 by market cap
Listed 2026
28.82
-0.04
-0.14%
Live - 5344 symbols - heartbeat 361s ago
· 2026-10-08 06:04
Pre-market
28.91
+0.32%
After-hours
28.82
0.00%
- Market cap
- 3.56B
- P/E (TTM)i
- -15.17
- P/Bi
- 3.40
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on PBLS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 3.7 percentage points.
Institutional ownership
- Held by institutions
- 84.59% -3.69pp
- Institutions
- 86
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund50.86%
Mutual Fund19.91%
Hedge Fund10.43%
Public Company3.40%
Other15.31%
Top holders as of 2026-07-22
RA Capital Management, L.P.
23.62% · 29.18M sh
FMR
8.33% · 10.29M sh
Arch Venture Partners, L.P.
5.19% · 6.41M sh
venBio LLC
4.26% · 5.27M sh
GV Management Company, LLC
3.98% · 4.92M sh
Nextech Invest Ltd.
3.77% · 4.66M sh
Cormorant Asset Management, LP
3.74% · 4.62M sh
Mwg Management Ltd.
3.70% · 4.57M sh
Regeneron Pharmaceuticals, Inc.
3.37% · 4.17M sh
Artal Group S.A.
2.42% · 2.99M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
33 filings tracked · 23 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 23.62% |
| Alexis Borisy | Independent Director | 0.09% |
| Edward Fitzgerald | Independent Director | 0.01% |
| Alan Sebulsky | Independent Director | -- |
| Deerfield Management Company, L.P. | -- | -- |
| Richard Klausner | Independent Director | -- |
| Apothecary Capital LLC | -- | -- |
| Mathai Mammen | CEO, President, Treasurer & Chairman | -- |
| Krishna Yeshwant | Independent Director | -- |
| Barbara Weber | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-21 | Craig Tendler | Director & Scientific Advisor | Other Derivative Acquisition | +20,294 | $39.36 |
| 2026-08-21 | Craig Tendler | Director & Scientific Advisor | Initial Statement of Beneficial | 0 | -- |
| 2026-07-21 | RA Capital Management, L.P. | -- | Open Market Acquisition | +244,593 | $27.13–30.00 |
| 2026-06-14 | Apothecary Capital LLC | -- | Open Market Acquisition | +17,500 | $26.00–27.67 |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +3,666 | -- |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +5,332 | -- |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +8,111 | -- |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Derivative Exercise and Retained | +14,688 | -- |
| 2026-06-10 | Alexis Borisy | Independent Director | Other Derivative Acquisition | +162,221 | -- |
| 2026-06-10 | Alexis Borisy | Independent Director | Derivative Exercise and Retained | +105,414 | -- |
| 2026-06-10 | Deerfield Management Company, L.P. | -- | Derivative Exercise and Retained | +1,880,704 | -- |
| 2026-06-10 | Apothecary Capital LLC | -- | Private Acquisition | +12,500 | $20.00 |
| 2026-06-10 | RA Capital Management, L.P. | -- | Private Acquisition | +21,188,750 | $20.00 |
| 2026-06-10 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +7,744,621 | -- |
| 2026-06-10 | Soleus Capital Management, L.P. | -- | Private Acquisition | +500,000 | $20.00 |
| 2026-06-10 | Soleus Capital Management, L.P. | -- | Derivative Exercise and Retained | +527,070 | $9.48 |
| 2026-06-08 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +20,215 | $20.00 |
| 2026-06-08 | Edward Fitzgerald | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-08 | Alan Sebulsky | Independent Director | Other Derivative Acquisition | +39,792 | $20.00 |
| 2026-06-08 | Alexis Borisy | Independent Director | Other Derivative Acquisition | +20,215 | $20.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:04:39 · For reference only, not investment advice and not tailored to your situation.